Richard Paul Rothman

US Patent:

6387389, May 14, 2002

Filed:

Jun 30, 1999

Appl. No.:

09/269926

Inventors:

Richard B. Rothman - Bethesda MD
Kenner C. Rice - Bethesda MD
David Lewis - Rockville MD
Dorota Matecka - Washington DC
John R. Glowa - Shreveport LA

Assignee:

The United States of America as represented by the Secretary of the Department of Health and Human Services - Washington DC

International Classification:

A61F 1300

US Classification:

424422, 424465, 51425211, 51425213, 51425305, 51425306, 51425312, 51425402, 51425405, 51425409, 5142541, 51425411, 51425504, 544357, 544360, 544363, 544366, 544368, 544370, 544373, 544376, 544379, 544380, 544384, 544385, 544397

Abstract:

The present invention provides sustained-release derivatives of hydroxylated analogs of substituted 1-[2[bis(aryl)methoxy]ethyl]-piperazines and -homopiperazines, pharmaceutical compositions comprising the same, and a method of using such sustained-release derivatives to bind the dopamine transporter to achieve a desired effect, such as antagonism of dopamine reuptake inhibitors, such as cocaine, or dopamine releasers or norepinephrine and/or serotonin reuptake inhibitors, such as methamphetamine.

US Patent:

20130217588, Aug 22, 2013

Filed:

Jan 21, 2009

Appl. No.:

12/998621

Inventors:

Samuel Yang - Columbia MD, US
Richard Rothman - Cockeysville MD, US
Charlotte Gaydos - Bel Air MD, US

Assignee:

THE JOHNS HOPKINS UNIVERSITY - Baltimore MD

International Classification:

G01N 21/64
C40B 30/04
C12Q 1/68

US Classification:

506 9, 435 611

Abstract:

This invention relates, e.g., to methods for detecting a aubacterium, determining if the eubacterium is Gram-positive or Gram-negative, and determining the species of the eubacterium in a sample.

US Patent:

6207699, Mar 27, 2001

Filed:

Jun 18, 1999

Appl. No.:

9/335841

Inventors:

Richard Brian Rothman - Bethesda MD

International Classification:

A61K31/40;31/31;31/195

US Classification:

514419

Abstract:

Numerous studies have documented that medications which increase brain serotonin (5-HT) are effective anorectic agents which help obese patients lose weight and which also decrease craving for sweets and carbohydrates. Evidence from other studies also indicate that increases in brain 5-HT may help decrease craving for alcohol and cocaine. 5-hydroxy-L-tryptophan, abbreviated 5-HTP, is the immediate precursor of serotonin (5-HT). When administered in combination with an inhibitor of peripheral decarboxylase such as carbidopa, 5-HTP increases brain serotonin. Increases in synaptic 5-HT decreases the firing rate of 5-HT neurons via stimulation of inhibitory 5-HT1a receptors located on the cell bodies in the raphe. This serves as a negative feedback loop. The clinically available beta adreneric receptor antagonist medication pindolol is also a 5-HT1a antagonist, and can be used to increase the ability of 5-HTP to increase brain 5-HT.

US Patent:

57475032, May 5, 1998

Filed:

Nov 12, 1996

Appl. No.:

8/746517

Inventors:

Richard Rothman - Silver Spring MD
Frank I. Carroll - Durham NC
Bruce Blough - Raleigh NC
Samuel W. Mascarella - Hillsborough NC

Assignee:

The United States of America as represented by the Department of Health
and Human Services - Washington DC
Research Triangle Institute - Research Triangle Park NC

International Classification:

C07D22122
A61K 3146

US Classification:

514294

Abstract:

The present invention provides a compound having the structure: ##STR1## wherein X, Y, and Z are independently H, Cl, Br, F, OCH. sub. 3, I, or an alkyl group having 1 to 6 carbon atoms; and R is ##STR2## wherein n is 0 to 6, X' and Y' are independently H, Cl, F, CH. sub. 3, C. sub. 2 H. sub. 5, C. sub. 3 H. sub. 7, C. sub. 4 H. sub. 9, OCH. sub. 3, OH, CF. sub. 3, OCF. sub. 3, NO. sub. 2, NH. sub. 2, N(CH. sub. 3). sub. 2, NHCOCH. sub. 3, NCS, NHCOCH. sub. 2 Br, or N. sub. 3, and (CH. sub. 2). sub. n, if present, may be substituted with OH, OCH. sub. 3, or an alkyl or alkenyl group having 1 to 3 carbon atoms. The present invention also provides a pharmaceutical composition comprising the compound above and a pharmaceutically acceptable carrier. The present invention further provides a method for treating a disease characterized by a dopamine deficiency which comprises administering to a subject in need of such treatment an amount of the pharmaceutical composition above effective to treat the disease.

US Patent:

52083381, May 4, 1993

Filed:

Jun 14, 1991

Appl. No.:

7/715762

Inventors:

Brian R. de Costa - Gaithersburg MD
Michael J. Iadarola - Washington DC
Kenner C. Rice - Bethesda MD
Richard B. Rothman - Silver Spring MD
Karen F. Berman - Washington DC

Assignee:

The United States of America as represented by the Department of Health
& Human Services. - Washington DC

International Classification:

A61K 4300
A61K 4902
C07D48908

US Classification:

546 44

Abstract:

The present invention is directed to radiolabeled N-substituted-6-iodo-3,14-dihydroxy-4,5. alpha. -epoxymorphinans, intermediates for producing the same, and a process for the preparation and methods of detecting opioid receptors. The radioimaging agent of the present invention has the following formula: ##STR1## wherein I is selected from the group consisting of. sup. 123 I and. sup. 125 I; and where R is alkyl, cycloalkylloweralkyl or allyl.

US Patent:

55740600, Nov 12, 1996

Filed:

Feb 28, 1994

Appl. No.:

8/203222

Inventors:

Richard Rothman - Silver Spring MD
Frank J. Carroll - Durham NC
Bruce Blough - Raleigh NC
Samuel W. Mascarella - Hillsborough NC

Assignee:

The United States of America as represented by the Department of Health
and Human Services - Washington DC
Office of Technology Transfer - Bethesda MD
Research Triangle Institue - Research Triangle Park NC

International Classification:

A61K 3140
A61K 3147
C07D40306
C07D47108

US Classification:

514411

Abstract:

The present invention provides a compound having the structure: ##STR1## wherein X, Y, and Z are independently H, Cl, Br, F, OCH. sub. 3, I, or an alkyl group having 1 to 6 carbon atoms; and R is ##STR2## wherein n is 0 to 6, X' and Y' are independently H, Cl, F, CH. sub. 3, C. sub. 2 H. sub. 5, C. sub. 3 H. sub. 7, C. sub. 4 H. sub. 9, OCH. sub. 3, OH, CF. sub. 3, OCF. sub. 3, NO. sub. 2, NH. sub. 2, N(CH. sub. 3). sub. 2, NHCOCH. sub. 3, NCS, NHCOCH. sub. 2 Br, or N. sub. 3, and (CH. sub. 2). sub. n, if present, may be substituted with OH, OCH. sub. 3, or an alkyl or alkenyl group having 1 to 3 carbon atoms. The present invention also provides a pharmaceutical composition comprising the compound above and a pharmaceutically acceptable carrier. The present invention further provides a method for treating a disease characterized by a dopamine deficiency which comprises administering to a subject in need of such treatment an amount of the pharmaceutical composition above effective to treat the disease.

US Patent:

53364830, Aug 9, 1994

Filed:

Jan 13, 1993

Appl. No.:

8/003731

Inventors:

Brian R. de Costa - Gaithersburg MD
Michael J. Iadarola - Washington DC
Kenner C. Rice - Bethesda MD
Richard B. Rothman - Silver Spring MD
Karen F. Berman - Washington DC

Assignee:

The United States of America as represented by the Department of Health
and Human Services - Washington DC

International Classification:

A61K 4902
C07D48908

US Classification:

424 185

Abstract:

The present invention is directed to radiolabeled N-substituted-6-iodo-3,14-dihydroxy-4,5. alpha. -epoxymorphinans, intermediates for producing the same, and a process for the preparation and methods of detecting opioid receptors. The radioimaging agent of the present invention has the following formula: ##STR1## wherein I is selected from the group consisting of. sup. 123 L and. sup. 125 ; and where R is alkyl, cycloalkylloweralkyl or allyl.